Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06451965 Active, not recruiting - Clinical trials for Post-stroke Depression

SCED - Wisdom Enhancement for Post-Stroke Depression

WE-PSD
Start date: September 1, 2023
Phase: N/A
Study type: Interventional

One-third of stroke survivors experience post-stroke depression, but there are currently no official guidelines for supporting them. Researchers aim to investigate whether the wisdom enhancement timeline technique can reduce depression in stroke survivors. The investigators also want to understand how this technique positively impacts mood, identity, self-esteem, and wisdom. The study will involve nine stroke survivors from the National Health Service (NHS) to gain insights into effective ways to support those with post-stroke depression.

NCT ID: NCT06364436 Active, not recruiting - Clinical trials for PostPartum Depression

Distant Reiki Therapy on Postpartum Period Fatigue and Depression

Start date: June 3, 2022
Phase: N/A
Study type: Interventional

This research was conducted to evaluate the effect of Reiki therapy applied to women in the postpartum period on the risk of fatigue and postpartum depression.

NCT ID: NCT06332261 Active, not recruiting - Clinical trials for Major Depressive Disorder

Standardized Assessment in Depression Treatment in Routine Psychiatric Services

Start date: March 8, 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate current practices in depression treatment in psychiatric services in Stockholm, Sweden. The main questions it aims to answer are: - Are current practices consistent with local clinical guidelines in terms of standardized assessment and the treatments provided? - What are the present conditions for implementing measurement-based care in depression treatment in this setting? Data will be collected retrospectively from medical records of patients having received psychological or pharmacological treatment for depression from 2020 to 2023. Frequency of standardized assessments (not scores) using the Montgomery-Åsberg Depression Rating Scale, the Montgomery-Åsberg Depression Rating Scale-Self Assessment, and the Patient Health Questionnaire-9 is collected, together with information on patient, clinician, and treatment characteristics.

NCT ID: NCT06320028 Active, not recruiting - Depression Clinical Trials

Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms

DMNtFUS
Start date: April 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Depression is a leading cause of disability worldwide, affecting roughly 21 million adults. Repetitive Negative Thought (RNT) has been identified as a potential maintaining factor in depression, such that those who exhibit higher degrees of RNT endorse greater symptoms. Research also suggests that the Default Mode Network (DMN), responsible for self-referential processing, plays an important role in depression wherein it has been linked to RNT. In depressed individuals, this network appears to be hyper-connected, or "too connected", within itself which, in turn, is thought to promote RNT. Half of depressed individuals are treatment-resistant, creating a critical need to identify more effective interventions derived from a better mechanistic understanding of the development and maintenance of depression. Non-invasive Transcranial-Focused Ultrasound Stimulation (tFUS) is promising for the treatment of depression. tFUS directs a low-intensity (nonthermal) focused ultrasound beam that passes safely through the skull. Compared to other noninvasive neuromodulation approaches, tFUS can target deeper brain regions with high spatial precision. The present study is an exploratory non-blinded single treatment study to investigate whether tFUS targeting a major hub of the DMN, the anterior-medial prefrontal cortex, can improve depression symptoms and reduce RNT. Twenty depressed individuals with high RNT (75th percentile) will complete up to eleven ultrasound sessions targeting the anterior medial prefrontal cortex, a hub of the brain's default mode network that has been found to be hyper-connected in depression. MRI scans will be obtained before the first and after the last ultrasound sessions. Based on previous literature, it is predicted that depression interview ratings and self-report symptoms will decrease after the intervention, and also that DMN connectivity will decrease following intervention.

NCT ID: NCT06234696 Active, not recruiting - Depression Clinical Trials

Cognitive Behavioral Therapy by Humor Based Psychoeducation

Start date: December 30, 2022
Phase: N/A
Study type: Interventional

This study aims to reveal the effectiveness of based cognitive behavioral therapy by humor based psychoeducation on sense of humour, self-esteem and depressıon level patient in diagnosed with deppression .

NCT ID: NCT06234371 Active, not recruiting - Depression Clinical Trials

Financial Incentives for Veteran Therapy Completion

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

Recovery Resource Council (RRC) is one of the largest and most comprehensive non-profit mental and behavioral healthcare providers in North Texas. Accredited by the Joint Commission in Behavioral Health and licensed by the State of Texas as an Outpatient Treatment Center, RRC strives to promote wellness and recovery through a variety of services and programming. An important component of RRC programming is providing free counseling services to hundreds of U.S. veterans annually. While RRC observes great success for veterans who complete counseling, attendance can be a major obstacle. Veterans who approach RRC for individual counseling services and consent to participate will be randomly assigned to the treatment or control group. The control group will receive counseling as usual. The treatment group will receive $500 gift card payments upon completing their 6th, 12th, and 18th counseling sessions, i.e., $1,500 in gift cards for completing all 18 sessions, the usual prescribed length of therapy. Our primary focus is to examine the impact of the financial incentives on therapy attendance and attrition. In addition, the investigators will estimate the impact on mental health using mental health inventories collected over the course of therapy sessions.

NCT ID: NCT06126497 Active, not recruiting - Clinical trials for Major Depressive Disorder

Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients

Start date: February 5, 2024
Phase: Phase 2
Study type: Interventional

This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressive Disorder (MDD).

NCT ID: NCT06119854 Active, not recruiting - Depression Clinical Trials

Brief Digital Intervention to Increase COVID-19 Vaccination Among Individuals With Anxiety or Depression

Start date: April 15, 2024
Phase: N/A
Study type: Interventional

The COVID-19 pandemic has led to a mis/disinformation ecosystem that promotes divergent views of vaccine efficacy, as well as the legitimacy of science and medicine. Individuals are confronted with vaccine-related information from a multitude of sources, posing a challenge to identifying inaccurate information. COVID-19 vaccine uptake is lower among people with anxiety and depression than in the general population, due in part to higher levels of vaccine hesitancy. The prevalence of anxiety and depressive symptoms among US adults increased significantly during the COVID pandemic and has remained elevated. Interventions capable of mitigating the impact of vaccine hesitancy and mis/disinformation among undervaccinated people with anxiety or depression are therefore an urgent priority. Emerging evidence suggests that reasons for vaccine hesitancy and the impact of conventional vaccination messaging differ between those with and without mental health symptoms. There may also be added challenges overcoming logistical barriers to vaccination for people with anxiety or depressive symptoms. The investigators aim to determine the effectiveness of two different brief digital intervention strategies compared with conventional public health messaging for increasing vaccine uptake in undervaccinated adults with and without anxiety or depressive symptoms. Attitudinal inoculation is a brief, scalable strategy that leverages the power of narrative, values, and emotion to strengthen resistance to mis/disinformation and reduce hesitancy. Though this approach has been shown to decrease COVID-19 vaccine hesitancy among US adults, the extent to which this approach increases COVID-19 vaccination remains unknown. Cognitive-behavioral therapy (CBT) is an evidence-based intervention for anxiety and depression. However, the efficacy of incorporating CBT-informed messaging in a vaccine promotion intervention has not been tested. The investigators hypothesize that both attitudinal inoculation and CBT-style communication will be more effective than conventional public health messaging to increase COVID-19 vaccination. The investigators also hypothesize that the CBT-informed intervention will be more effective than the attitudinal inoculation intervention for increasing COVID-19 vaccination among participants with symptoms of anxiety or depression.

NCT ID: NCT06028984 Active, not recruiting - Clinical trials for Major Depressive Disorder

Self-guided Treatment for Depression

Start date: October 12, 2023
Phase: N/A
Study type: Interventional

This study will examine the efficacy and safety of a self-guided digital therapeutic app for the adjunct treatment of Major Depressive Disorder compared to a control app in adolescents and adults.

NCT ID: NCT06013137 Active, not recruiting - Depression Clinical Trials

Chatbot for Depression, Anxiety, and Eating Disorders

Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The research team would like to test how efficacious an artificial intelligence chatbot is in delivering supportive behavioral interventions in populations with anxiety, depression, or eating concerns.